1. Home
  2. RDHL vs ELAB Comparison

RDHL vs ELAB Comparison

Compare RDHL & ELAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDHL
  • ELAB
  • Stock Information
  • Founded
  • RDHL 2009
  • ELAB 2020
  • Country
  • RDHL Israel
  • ELAB United States
  • Employees
  • RDHL N/A
  • ELAB N/A
  • Industry
  • RDHL Biotechnology: Pharmaceutical Preparations
  • ELAB
  • Sector
  • RDHL Health Care
  • ELAB
  • Exchange
  • RDHL Nasdaq
  • ELAB Nasdaq
  • Market Cap
  • RDHL 3.9M
  • ELAB 3.2M
  • IPO Year
  • RDHL N/A
  • ELAB 2023
  • Fundamental
  • Price
  • RDHL $1.57
  • ELAB $5.95
  • Analyst Decision
  • RDHL
  • ELAB
  • Analyst Count
  • RDHL 0
  • ELAB 0
  • Target Price
  • RDHL N/A
  • ELAB N/A
  • AVG Volume (30 Days)
  • RDHL 1.5M
  • ELAB 1.4M
  • Earning Date
  • RDHL 09-05-2025
  • ELAB 11-13-2025
  • Dividend Yield
  • RDHL N/A
  • ELAB N/A
  • EPS Growth
  • RDHL N/A
  • ELAB N/A
  • EPS
  • RDHL N/A
  • ELAB N/A
  • Revenue
  • RDHL $9,550,000.00
  • ELAB N/A
  • Revenue This Year
  • RDHL $381.91
  • ELAB N/A
  • Revenue Next Year
  • RDHL N/A
  • ELAB N/A
  • P/E Ratio
  • RDHL N/A
  • ELAB N/A
  • Revenue Growth
  • RDHL 157.62
  • ELAB N/A
  • 52 Week Low
  • RDHL $1.06
  • ELAB $4.29
  • 52 Week High
  • RDHL $8.75
  • ELAB $515.79
  • Technical
  • Relative Strength Index (RSI)
  • RDHL 43.92
  • ELAB 49.63
  • Support Level
  • RDHL $1.64
  • ELAB $5.83
  • Resistance Level
  • RDHL $1.90
  • ELAB $8.78
  • Average True Range (ATR)
  • RDHL 0.16
  • ELAB 0.86
  • MACD
  • RDHL -0.03
  • ELAB -0.18
  • Stochastic Oscillator
  • RDHL 10.94
  • ELAB 15.52

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

About ELAB Elevai Labs Inc.

PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.

Share on Social Networks: